Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.

Expression of CD7, ELA-2, PR-3, and the polycomb group gene BMI-1 reflects the intrinsic heterogeneity and predicts prognosis of patients with chronic myeloid leukemia (CML) who were not treated with allogeneic stem cell transplantation (allo-SCT). This study investigated whether expression of these genes determined outcome following allo-SCT in a cohort of 84 patients with chronic-phase (CP) CML. We found that patients expressing BMI-1 at a "high" level before allo-SCT had an improved overall survival (P = .005) related to a reduced transplantation-related mortality. In multivariate analysis, when adjusted for the European Group for Blood and Marrow Transplantation (EBMT)-Gratwohl score and other prog-nostic factors, there was an independent association between BMI-1 expression and grades 2 to 4 acute graft-versus-host disease (relative risk [RR] = 2.85; 95% confidence interval [CI], 1.3-6.4; P = .011), suggesting that BMI-1 measured prior to allo-SCT can serve as a biomarker for predicting outcome in patients with CP-CML receiving allo-SCT, and may thus contribute to better therapeutic decisions.

[1]  K. Rezvani,et al.  High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. , 2007, Blood.

[2]  C. Craddock,et al.  CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. , 2007, Blood.

[3]  H. Hosokawa,et al.  Regulation of Th2 Cell Development by Polycomb Group Gene bmi-1 through the Stabilization of GATA31 , 2006, The Journal of Immunology.

[4]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Kimura,et al.  Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. , 2006, Blood.

[6]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[7]  John P Klein,et al.  Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants , 2004, British journal of haematology.

[8]  J. Melo,et al.  The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. , 2007, Blood.

[9]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[10]  E. Vellenga,et al.  Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. , 2008, Blood.

[11]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Lancet.

[12]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[13]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[14]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[15]  A. Gratwohl,et al.  Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerations , 2007, Leukemia.

[16]  A. Gratwohl,et al.  Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. , 1995, Blood.

[17]  M. Mohty,et al.  Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. , 2008, Cytokine & growth factor reviews.

[18]  G. Sauvageau,et al.  Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells , 2003, Nature.

[19]  R. Bouabdallah,et al.  Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. , 2005, Blood.

[20]  Chang-Nam Kim,et al.  The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. , 2004, Cancer letters.

[21]  M. Ohtaki,et al.  Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia , 2007, Leukemia.

[22]  Irving L. Weissman,et al.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.

[23]  P. Moss,et al.  The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens , 2006, British Journal of Cancer.

[24]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[25]  J. Melo,et al.  Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. , 2006, Blood.

[26]  E. Campo,et al.  BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. , 2001, Cancer research.

[27]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.